Bahl & Gaynor Inc. Purchases 570 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bahl & Gaynor Inc. lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,656 shares of the medical equipment provider’s stock after acquiring an additional 570 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Intuitive Surgical were worth $3,932,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Portside Wealth Group LLC lifted its holdings in shares of Intuitive Surgical by 8.2% in the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after acquiring an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter worth about $230,000. Blair William & Co. IL lifted its holdings in shares of Intuitive Surgical by 3.1% in the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after acquiring an additional 11,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Intuitive Surgical by 21.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock worth $216,140,000 after acquiring an additional 129,194 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 0.6 %

Shares of Intuitive Surgical stock opened at $375.33 on Friday. The firm’s 50 day moving average price is $386.19 and its 200-day moving average price is $345.95. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The company has a market cap of $133.13 billion, a P/E ratio of 67.75, a PEG ratio of 4.82 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the firm earned $1.00 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, CEO Gary S. Guthart sold 24,325 shares of Intuitive Surgical stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $376.06, for a total value of $9,147,659.50. Following the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at approximately $3,544,365.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 20,296 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Gary S. Guthart sold 24,325 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the sale, the chief executive officer now directly owns 9,425 shares in the company, valued at approximately $3,544,365.50. The disclosure for this sale can be found here. Insiders have sold a total of 249,418 shares of company stock valued at $96,300,959 in the last 90 days. Insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ISRG. Truist Financial lifted their price objective on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Barclays lifted their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Jefferies Financial Group lifted their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Finally, Citigroup lifted their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.